Gyre Therapeutics
GYRE
63 hedge funds and large institutions have $66.4M invested in Gyre Therapeutics in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 8 closing their positions.
19% more call options, than puts
Call options by funds: $598K | Put options by funds: $504K
12% more capital invested
Capital invested by funds: $59.3M → $66.4M (+$7.08M)
0.73% more ownership
Funds ownership: 8.39% → 9.12% (+0.73%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
3% less funds holding
Funds holding: 65 → 63 (-2)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.71M |
| 2 |
Millennium Management
New York
|
+$2.33M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.86M |
| 4 |
SCM
Sio Capital Management
New York
|
+$1.39M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$3M |
| 2 |
NC
Nexthera Capital
New York
|
-$2.97M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$857K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$450K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$370K |
GYRE Hedge Fund Activity: Q1 2019 in Review
63 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2019, worth a combined $66.4M — up 12% from $59.3M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GYRE and 7 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 22 added.
The largest buyer was Vanguard Group, adding an estimated $2.71M. The largest seller was Marshall Wace, cutting an estimated $3M.
- 63 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2019, down from 65 in Q4 2018.
- Funds reported $66.4M of Gyre Therapeutics stock for Q1 2019, up 12% quarter-over-quarter.
- 7 funds opened new Gyre Therapeutics positions in Q1 2019 and 8 closed out, a net change of -1 holder.
- The largest Gyre Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $2.71M added.
- The largest Gyre Therapeutics seller in Q1 2019 was Marshall Wace, an estimated $3M sold.
Based on aggregated 13F filings for Q1 2019.